Organisation paid for research Program year 2023 Source: CMS Open Payments

Breakthrough Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$516,285

305 payments

Through program year 2023, Breakthrough Clinical Trials is reported as receiving $516,285 in research payments, across 305 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $15,160 2
2022 Research $27,802 14
2021 Research $133,107 35
2020 Research $179,646 175
2019 Research $160,570 79

Breakdown

Who paid Research payments · program years 2019–2023
  1. Teva Pharmaceuticals USA, Inc. $421,381 237 payments
  2. H. Lundbeck A S $36,397 10 payments
  3. Pfizer Inc. $25,045 21 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $13,660 1 payment
  5. Neurocrine Biosciences, Inc. $11,024 34 payments
  6. Allergan Inc. $8,778 2 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $311,494 62 payments
  2. A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $70,388 16 payments
  3. An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia $39,499 159 payments
  4. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $25,045 21 payments
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia $13,660 1 payment
  6. Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension RESTORE $11,804 1 payment
  7. Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia $9,257 25 payments
  8. A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy $8,093 4 payments
  9. Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia Debut $6,500 1 payment
  10. A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $5,188 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record